Advancing Understanding of Neurodegenerative Disorders

This initiative is focused on improving the treatment and management of patients with neurodegenerative disorders, specifically multiple sclerosis (MS) and Huntington disease. Educational programs hosted here will give an in-depth review of the pathology and common pathways of neurodegenerative disorders. This includes the neuropathological changes with progressive forms of MS and the importance of the blood-brain barrier, the key drivers and outcome measures of disability progression in neurodegenerative diseases, the importance of personalized medicine in the management of neurodegenerative disorders, as well as the innovative approaches to determine the clinical condition of patients with Huntington disease.

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?
Hear Drs Comi and Cree discuss the applicability of NEDA in clinical practice and whether it is a predictor of disease stability.
June 23, 2017
What Does the Primary Care Physician Need to Know About Huntington Disease?
Case-based primer on Huntington disease diagnosis and management.
December 16, 2016
What Is the Role of Injectables in the Modern Era of MS Treatment?
Dr Ziemssen leads an expert discussion about the use of the classic, first-generation injectable therapies in patients with RRMS.
October 26, 2016
What Predicts Disability Progression in Multiple Sclerosis?
Drs Comi and Centonze discuss clinical and MRI predictors of disability progression in patients with multiple sclerosis.
October 24, 2016
Are We Making Progress in the Management of Huntington Disease?
Join Dr Reilmann and colleagues who discuss the burden of HD, current therapies for symptoms, and the outlook for disease-modifying therapy.
August 16, 2016
Managing MS Before, During, and After Pregnancy -- What Are the Options?
In this case study, Dr Coyle discusses issues that need to be taken into consideration when managing pregnant women with relapsing MS.
April 22, 2016
Huntington Disease: A Field on the Move -- Biomarkers and Future Therapies
HD experts discuss development and application of new assessment tools and imaging technologies and the use of novel biomarkers in HD trials.
January 19, 2016
Progressive Forms of Multiple Sclerosis: A Changing Paradigm?
Dr Gavin Giovannoni leads an expert panel discussion about the neuropathology of PPMS and how it might influence decisions about treatment options.
December 16, 2015
Huntington Disease: The Clinical Condition and an Update on Therapeutic Developments
A wide-ranging discussion by 2 Huntingtons disease research leaders on new assessment tools, clinical trial endpoints, and therapeutics in development.
November 30, 2015

Steering Committee Chair

Giancarlo Comi, MD
Professor of Neurology;
Chairman,
Specialization School in Neurology,
University Vita-Salute San Raffaele;
Director,
Department of Neurology,
Scientific Institute San Raffaele,
Milan, Italy

Steering Committee Members

Kevin M. Biglan, MD
Professor of Neurology; Associate Chair of Clinical Research Movement Disorders Division, University of Rochester Medical Center, Rochester, New York
Diego Centonze, MD, PhD
Full Professor of Neurology, Department of Systems Medicine, University of Rome Tor Vergata; Head, Experimental Neurology Laboratory, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Director, Unit of Neurology, Unit of Neurorehabilitation, IRCCS Istituto Neurologico Mediterraneo Neuromed,
Pozzilli (IS), Italy
Patricia K. Coyle, MD
Professor, Department of Neurology; Vice Chair, Clinical Affairs; Director, Multiple Sclerosis Comprehensive Care Center, Stony Brook University Medical Center,
Stony Brook, New York

G. Bernhard Landwehrmeyer, MD, PhD, FRCP
Ulm University Hospital, Department of Neurology
Tiago A. Mestre, MD, MSc
Assistant Professor, Division of Neurology, Department of Medicine, University of Ottawa; Researcher, Ottawa Hospital Research Institute, Brain and Mind Research Institute

Supported by an independent educational
grant from

Steering Committee

Giancarlo Comi, MD

Giancarlo Comi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Almirall, S.A.; Bayer HealthCare; Biogen Idec Inc.; Chugai Pharma USA, LLC; Excemed; Genzyme Corporation; Merck Serono; Novartis Pharmaceuticals Corporation; Receptos; Roche; Sanofi; Serono Symposia Int. Foundation; Teva Europe
Served as a speaker or a member of a speakers bureau for: Almirall, S.A.; Bayer HealthCare; Biogen Idec Inc.; Chugai Pharma USA, LLC; Excemed; Genzyme Corporation; Merck & Co., Inc.; Merck Serono; Novartis Pharmaceuticals Corporation; Receptos; Sanofi; Serono Symposia Int. Foundation; Teva Europe

Kevin M. Biglan, MD

Kevin M. Biglan, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: KJT Consulting Services, UCB Pharma, Inc.
Received grants for clinical research from: Lundbeck, Inc.

Patricia K. Coyle, MD

Patricia K. Coyle, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Accordant; Acorda Therapeutics; Bayer HealthCare; Biogen Idec Inc.; Genentech, Inc.; Genzyme Corporation; Mallinckrodt Pharmaceuticals; Merck Serono; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Teva Neuroscience, Inc.
Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Opexa Therapeutics, Inc.; Roche

G. Bernhard Landwehrmeyer, MD, PhD, FRCP

G. Bernhard Landwehrmeyer, MD, PhD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Desitin Arzneimittel GmbH; Isis Pharmaceuticals, Inc.; Pfizer Inc; Raptor Pharmaceutical, Inc.; Roche; Siena Biotech; Teva Europe

Tiago A. Mestre, MD, MSc

Tiago A. Mestre, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.
Served as a speaker or a member of a speakers bureau for: Teva Pharmaceutical Industries Ltd.